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STRUCTURED ABSTRACT   97 
Background  98 
Long-active reversible contraceptives (LARCs) reduce nintended pregnancy and abortions 99 
but uptake is low. Interventions to increase uptake in family medicine settings are untested.  100 
Objective 101 
The Australian Contraceptive ChOice pRoject (ACCORd), a apted from the successful US 102 
Contraceptive CHOICE study, aimed to evaluate whether a complex intervention in family 103 
medicine practices resulted in increased LARC uptake by women.  104 
Study design 105 
This cluster randomized controlled trial was set in family practices in metropolitan 106 
Melbourne, Australia. From April 2016 to January 2017 we recruited 57 family physicians by 107 
mail invitation. Each family physician aimed to recruit at least 14 women patients. Eligible 108 
family physician worked three or more sessions per week in computerized practices. Eligible 109 
women were English speaking, sexually active, not pregnant, not planning a pregnancy in the 110 
following year, aged 16–45 years and interested in discussing contraception or in starting a 111 
new, reversible method. Using a randomization sequence with permuted bocks stratified by 112 
whether the family physician performed LARC insertion or not, family physicians were 113 
randomly assigned to a complex intervention involving training to provide structured 114 
effectiveness-based contraceptive counselling, and access to rapid referral to LARC insertion 115 
clinics. The six-hour, online educational interventio  was based on the US Contraceptive 116 
CHOICE Project and adapted for the Australian context. The control family physicians 117 
received neither the educational intervention nor access to the LARC rapid referral clinics 118 
and conducted their usual contraception counselling. We used the χ2 test, adjusted for 119 
clustering and stratification by whether the family physician inserted LARCs, and binary 120 




compare the proportions of women who had a LARC inserted between the intervention and 122 
control groups. The primary outcome was the proportion of women with LARCs inserted at 4 123 
weeks. Secondary outcomes included women’s choice of ontraceptive method, quality of 124 
life (QOL) and LARC use at 6 and 12 months. Analyses w re performed according to 125 
intention-to-treat.  126 
Results  127 
A total of 25 intervention and 32 control family physicians recruited 307 and 433 women 128 
respectively (N=740). Within 4 weeks 19.3% of women in the intervention group and 12.9% 129 
of women in the control group had LARC inserted (RR 2.0, 95% CI 1.1 to 3.9; P=0.033). By 130 
6 months this had risen to 44.4% and 29.3% respectively (RR 1.6, 95% CI 1.2 to 2.17; 131 
P<0.001) and by 12 months to 46.6% and 32.8% respectively (RR 1.5, 95% CI 1.2 to 2.0; 132 
P=0.0015). The levonorgestrel intra-uterine system was the most commonly chosen LARC 133 
by women in the intervention group at all time points. Differences between intervention and 134 
control groups in mean QOL scores across all domains t 6 and 12 months were small. 135 
Conclusions 136 
A complex intervention combining family physician training on contraceptive effectiveness 137 
counselling and rapid access to LARC insertion clini s resulted in greater LARC uptake and 138 
has the potential to reduce unintended pregnancies.  139 
 140 





International evidence shows that the increased use of long-acting reversible contraceptives 143 
(LARCs), defined as intrauterine devices (IUDs) andcontraceptive implants, can reduce 144 
unintended pregnancy and abortion rates across all tages of a woman’s reproductive life.1-4  145 
LARCs are the most effective reversible methods of contraception with typical-use failure 146 
rates for women of 0.05 to 0.8% in the first-year of use compared with 9% with the oral 147 
contraceptive pill and 18% with male condoms.5 LARCs are highly acceptable to women and 148 
also have higher continuation rates than other less-effective forms of contraception.6 7  149 
Despite this evidence, the prescription and use of LARCs remains low. In the UK LARC 150 
prescription by FPs fell by 6% from 2014-2016.8 In the United States, LARC uptake is 151 
increasing, but is around 14%.9 Australia has similarly low rates with national data from 152 
2012-2013 reporting that only 11% of women were using a LARC (6.1% for IUDs and 4.9% 153 
for implants).10 154 
In the US-based Contraceptive CHOICE Project (CHOICE), a prospective cohort study of 155 
9,526 women aged between 14-45,11 provision of evidence-based information about all 156 
reversible contraceptive options through structured counselling as well as free provision of 157 
implants and intrauterine devices, led to a significant increase in the uptake of LARC 158 
compared to national averages.  This resulted in a 20-fold reduction in unplanned pregnancy 159 
rates at three years of follow-up compared with contraceptive pill, patch or ring-users3 and a 160 
significant reduction in abortion rates compared with the regional and national rates.12 A 161 
subsequent randomized controlled trial, also undertak n in reproductive health clinics in the 162 
US, trained health care providers in LARC counselling and insertion but maintained normal 163 
costs to replicate real-life conditions. This study resulted in increased rates of counselling and 164 
LARC uptake in the intervention arm and reduced pregnancy rates in women attending for 165 




These two studies, both undertaken in specialised clinic settings, demonstrated that 167 
improving health care provider knowledge and skills, as well as addressing some of the 168 
financial and service access barriers,14 can impact women’s uptake of LARC. However, in 169 
many countries, including Australia, specialised reproductive health services are not widely 170 
available and women rely on their family physician (FP) for contraceptive counselling and 171 
provision. While the barriers to primary care provision of LARC have been well 172 
documented,4 14 no studies to our knowledge have tested interventions n this setting. 173 
Consequently, this study sought to compare a complex int rvention on the uptake of LARC 174 
in the family medicine practice setting. 175 
 176 
MATERIALS AND METHODS 177 
Trial Design and Oversight 178 
The ACCORd trial was set in metropolitan Melbourne, Australia with the FP as the unit of 179 
randomisation. Approved by the Monash University Human Research Ethics Committee: CF 180 
14/3990-2014002066 and CF 16/188-2016000080, and coforming to CONSORT 181 
guidelines,15 the study was conducted and reported with fidelity to the protocol described 182 
elsewhere.16 The conduct of the trial was periodically reviewed by an independent data safety 183 
monitoring committee consisting of a statistician and two academic researchers (independent 184 
from the ACCORd study) who monitored recruitment, trial outcomes and adverse events. The 185 
authors vouch for the accuracy and completeness of the data presented. 186 
Trial Population and Recruitment Procedures 187 
FPs were eligible if they worked three or more sessions (half days) per week, were based at a 188 
computerized practice and had reception staff who could assist with recruiting. FP 189 




the study gave written consent at enrolment. To avoid c ntamination due to cross-over 191 
effects, only one FP was included per practice.  Participating FPs were accredited with 192 
Continuing Professional Development points necessary to maintain professional FP 193 
qualifications and received $500 (AUD) as reimbursement for time spent on completion of 194 
the study.  195 
Reception staff from ACCORd FPs invited women to complete an online eligibility survey 196 
that included contact details using an iPad in the waiting room. Women were eligible to 197 
participate if they were aged between 16-45, had been s xually active with a male partner in 198 
the previous six months or anticipated sexual activity n the subsequent six months, had not 199 
undergone tubal ligation or hysterectomy, had sexual partners who had not undergone a 200 
vasectomy, were neither pregnant nor anticipating a pregnancy in the following 12 months, 201 
spoke proficient English and were interested in discus ing contraception or in starting a new, 202 
reversible contraceptive method.  203 
All eligible women were contacted by telephone by an ACCORd researcher to obtain consent 204 
and complete baseline questionnaires. After enrolment, women were asked to return to their 205 
ACCORd FP within one week for a contraceptive counselling appointment. Any additional 206 
charges for this visit were covered by ACCORd to ensure that the women did not bear out-of-207 
pocket costs for this additional visit. ACCORd did not provide coverage for the cost of 208 
individual contraceptive products. 209 
Randomisation and Masking 210 
The trial statistician generated a randomisation sequence with permuted blocks (block sizes 211 
of 4, 6 and 8), stratified by whether the FP performed LARC insertion (IUDs/implants) or 212 




ACCORD trial. When a FP was recruited, ACCORd staff contacted the research assistant to 214 
assign the FP to the next allocation in the sequence. 215 
Interventions 216 
FPs in the intervention arm were trained to deliver structured contraceptive counselling and 217 
given access to rapid referral to LARC insertion cli i s through an online booking system. 218 
Materials from the “LARC first” (contraceptive effectiveness) online training site of the 219 
Contraceptive CHOICE project3 were adapted to the Australian context with input from an 220 
advisory group comprising the project investigators, FPs, and consumers. Training was 221 
delivered online through a six-hour training package with additional practice visits, email, 222 
and telephone support where required. Structured contraceptive counselling18 consisting of 223 
non-biased, scripted descriptions of all available contraceptive methods, with particular 224 
reference to the safety and efficacy of each method, was then delivered to the participating 225 
women by the intervention trained FPs. FPs also colle ted clinical information from the 226 
women to identify any contraindications or conditions that may influence the choice of 227 
contraception. Women were able to choose their contraception method provided that it was 228 
not medically contraindicated. The FP was then advised to screen the woman for pregnancy 229 
(history and urine pregnancy test) and chlamydia (according to clinical practice guidelines 230 
published by the Royal Australian College of General P ctitioners).19 The online training 231 
recommended ruling out pregnancy before: (a) providing a prescription for the method of 232 
choice; (b) offering “same day” insertion of the LARC method, or at a subsequent time at the 233 
FP clinic; or (c) providing an appointment for insertion of the LARC method at one of the 234 
insertion clinics. Emergency contraception was advised for women who had recent 235 
unprotected intercourse, while “quick start” contraception (i.e. commencing contraception at 236 
any time rather than at the start of the next menstrual cycle) was recommended for women  in 237 




Healthcare guidelines).20 In both of these cases a return appointment in three to four weeks 239 
for a LARC insertion (and a repeat pregnancy test) was also recommended. 240 
A rapid referral pathway to a LARC insertion clinic with two local private gynecologists was 241 
implemented through an online booking system for intervention FPs who did not or chose not 242 
to perform insertions in their own rooms. Gynecologists providing these LARC insertion 243 
clinics received payment of $300 (AUD) per 3 ½ hour clinic undertaken and were free to 244 
charge patients their usual fees at these clinics.  245 
FPs in the control group provided usual contraceptiv  care to women recruited to this arm 246 
and did not have access to the rapid referral LARC insertion clinics. At the conclusion of the 247 
trial, the control group of FPs were invited to undertake the online contraceptive effectiveness 248 
training. 249 
Fidelity checking 250 
To ensure fidelity of the counselling, a researcher (blinded to the allocation of the FP to 251 
intervention or control arm) visited FPs in both groups. During this visit, the researcher 252 
observed a single consultation and completed a checklist regarding the content of the 253 
contraceptive counselling provided to ascertain whether the counselling was structured with 254 
an emphasis on effectiveness.  255 
Trial Measures 256 
At baseline eligible women undertook an initial telephone based questionnaire drawn from 257 
the US Contraceptive Choice Project3 and including the Health Literacy Questionnaire 258 
(HLQ),21 and Medical Outcomes Survey (SF-36).22 Further surveys were conducted online at 259 
6 months (including the SF-36) and at 12 months (including the HLQ and SF-36). After 260 
completing each survey women were given an entry ino a monthly prize draw for a $150 gift 261 




Participating FPs and gynecologists working in the LARC insertion clinics were asked to 263 
complete a standardised data collection form at every consultation involving an ACCORd 264 
participant. 265 
Primary and secondary outcomes 266 
The primary outcome was the proportion of women who had a LARC inserted within 4 267 
weeks of the initial contraceptive consultation with their FP. Secondary outcomes included 268 
women’s choice of contraceptive method, quality of life and LARC use at 6 and 12 months. 269 
These outcomes were measured using data sourced from the standardised data collection 270 
forms and from the 6 and 12 month surveys.  271 
Statistical analysis 272 
Current LARC use increased from 2.3% to 11% of all contraceptives use in Australia over a 273 
13 year time frame.10 23 A British study estimated that if 5% of British women who used oral 274 
contraceptives used LARC instead, the decrease in contraceptive failure would result in 7,500 275 
annual unplanned pregnancies.24 Therefore, we chose an effect size of 10%. We estimated 276 
that we would require 24 FPs and 24 women per FP in each of the two study arms 277 
(intervention and control) to detect a 10% increase in the LARC insertion rate, with 80% 278 
power and a significance level of 5% allowing for stratification according to whether or not 279 
FPs inserted LARCs and a clustering effect (intracluster correlation (ICC)) of 0.05. This 280 
corresponds to the maximum ICC for variables associated with FP–patient encounters in a 281 
recent cluster RCT 25 and other FP-specific studies.26 We aimed to recruit 27 FPs and 27 282 
women per FP in each of the two study arms to allow for up to a 10% drop-out among FPs 283 
and a 10% drop-out among women. 284 
We calculated counts and proportions for descriptive characteristics of FPs and women at 285 




inserted LARCs,  and binary regression models with generalized estimating equations and 287 
robust standard errors, to compare the proportions of women who had a LARC inserted (the 288 
primary outcome) between the intervention and control groups for women who had outcome 289 
data available. The outcomes for women were analysed according to their randomized group 290 
(intention-to-treat analysis). This method was also pplied to the secondary outcomes of 291 
LARC use at 6 and 12 months. Linear regression models also adjusting for study design were 292 
used to compare mean QOL scores between groups. We conducted sensitivity analyses by 293 
adjusting for the following variables: FP sex, FP age group, women’s age group, parity and 294 
use of LARC at baseline. Additional sensitivity analyses were carried out assuming that 295 
women with missing outcome data were not missing at random. For these analyses, we used 296 
multiple imputation under plausible missing data scenarios - women with missing outcome 297 
data had (1) the same probability of the outcome as tho e from the same arm; (2) the same 298 
probability of the outcome as those from the control a m; (3) the same probability of the 299 
outcome as those from the intervention arm; (4) no LARC inserted. Twenty imputation 300 
datasets were created in each analysis and the results were combined using Rubin’s rules. In 301 
the binary regression models we investigated whether the effect of the intervention varied 302 
across subgroups defined by age, parity, use of LARC at baseline, marital status, 303 
socioeconomic status, education, previous unintended pr gnancy and previous abortion using 304 
interaction terms. All analyses were carried out using SAS v9.4. 305 
Stakeholder involvement 306 
Prior to commencement of recruitment and prior to final ethics submission, the study tools 307 
(FP surveys) were piloted among five FPs who provided suggestions for amendment. FPs 308 
were also asked to assess the burden of intervention and the time required to participate in the 309 
study. 310 





Trial Sites and Participants 313 
From April 2016 to May 2017, 43 FPs were randomly alloc ted to the intervention group 314 
(with 25 subsequent withdrawals) and 44 to the control group (with 23 subsequent 315 
withdrawals). A total of 25 intervention FPs recruited at least one participant, as did 32 316 
control FPs (Figure 1). The characteristics of the FPs were well-balanced between the 317 
intervention and control groups (Table 1). The majority of the FPs were females, aged 35 to 318 
54 and inserted implants but not IUDs. Most FPs (81%) had 10 or more years of experience. 319 
Recognised training in contraception had been undertak n by 25% of FPs, and 40% of 320 
intervention FPs and 34% of control FPs also having specific training in IUD insertion (Table 321 
1). 322 
Between June 2016 and July 2017, intervention FPs recruited 410 women (103 women 323 
initially expressed an interest in the study but did not consent) and control FPs recruited 622 324 
women (189 women initially expressed an interest in the study but did not consent), resulting 325 
in 307 and 433 women in the intervention and control a ms respectively (N=740). The 326 
characteristics of the women were also well-balanced between the two groups (Table 1). This 327 
balance was retained among women with available data from the Standardised Data 328 
Collection Forms and from the 6 and 12 month survey. Most women were aged under 35 329 
years, had no children and were not currently using a LARC. The rate of cohort retention was 330 
71% in both groups.  331 




Primary and Secondary Outcomes 333 
Within 4 weeks of the contraceptive counselling consultation 8% more women in the 334 
intervention group than in the control group had haa LARC inserted (95% confidence 335 
interval (CI), 1.5 to 15.4  P=0.018) (Table 2), with ICC of 0.13.   336 
LARC uptake continued to rise with time at 6 and 12 months with a greater proportion of 337 
women in the intervention group (44% and 47%, respectiv ly) currently using a LARC 338 
compared to the control group (29% and 33%, respectively) (Table 2).  339 
The levonorgestrel IUS was the most commonly chosen LARC in the intervention group and 340 
the etonogestrel implant in the control group at the 4 week, 6 month and 12 month time 341 
points. (Table 3). None of the interaction tests indicated a differential effect of the 342 
intervention across subgroups defined by age, parity, use of LARC at baseline, marital status, 343 
socioeconomic status, education, previous unintended pr gnancy or previous abortion 344 
(Supplementary Table A1).  345 
The results of the primary outcome analysis were similar, although the effects were smaller, 346 
when covariates were adjusted for or when missing data were imputed under various 347 
assumptions. The P-values for the comparison of binary outcomes were similar when 348 
calculated using the χ2 test, adjusted for clustering and stratification or using binary 349 
regression with GEE for all outcomes except for insertion at 4 weeks where the P-values 350 
were 0.20 and 0.03, respectively (Supplementary Table A2). 351 
The differences between intervention and control grups in mean QOL scores across all 352 
domains at 6 and 12 months were small and unlikely to be of practical importance or clinical 353 
significance despite two of the comparisons being statistically significant. The statistically 354 





Process Data  357 
Fidelity checks were completed for nine interventio FPs and 12 control FPs. Initiation of 358 
structured efficacy-based contraceptive counselling was observed for 44% of the intervention 359 
FPs (n=4) compared with 8% of the control FPs (n=1). Also, the data monitoring committee 360 
met every three months during the recruitment and data collection phases of the study. No 361 
unexpected complications nor adverse-effects were not d in either group. 362 
 363 
STRUCTURED DISCUSSION / COMMENT 364 
Principal Findings 365 
The ACCORd trial results demonstrate that a family edicine practice based intervention 366 
consisting of online training in structured effectiveness-based contraceptive counselling and 367 
the provision of a rapid referral pathway to LARC insertion clinics results in increased LARC 368 
uptake.  Women participants of FPs who had received th se interventions were significantly 369 
more likely to have had a LARC inserted 4 weeks from eceipt of contraceptive counselling 370 
by their FP. This number increased by 6 months and increased further at 12 months.  371 
Results (in context of what is known) 372 
While ACCORd was modelled on the successful CHOICE study in the USA,11 our 373 
intervention differed from CHOICE in that it did not f cus on reducing the cost of 374 
contraceptive methods.   This suggests that in contexts such as Australia, where LARC 375 
uptake is poor despite universal health coverage and subsidised contraception, the cost of 376 
contraception for an individual woman may not impact on contraceptive decision-making as 377 
much as receiving structured effectiveness-based contraceptive counselling and the 378 
availability of a timely pathway to LARC insertion. Indeed the effect of the intervention did 379 




Lack of FP training in LARCs and LARC insertion has been identified as a barrier to 381 
increasing LARC uptake.14 Even with training, FPs often face difficulties sustaining practice 382 
in LARC insertion, with one study finding that only about 30% of those trained in LARC 383 
insertions continued to insert 12 or more devices per year, the minimum suggested by experts 384 
to maintain skill levels.27 The ACCORd intervention did not train FPs to insert LARCs. 385 
Despite this it still achieved increased rates of LARC uptake. This may be because the 386 
ACCORD intervention addressed other barriers that have been well described in the literature 387 
such as tackling the myths and misconceptions concerning  LARCs held by both FPs 388 
(through the training) and women (through structured effectiveness focused counselling) and 389 
by making LARC insertion more accessible through rapid referral pathways to insertion 390 
clinics.  391 
Clinical Implications 392 
Our findings are important as ACCORd is the first tial to extend the efficacy demonstrated 393 
by providing LARC education to doctors in reproductive health and family planning clinics9 394 
to a new and important site - family practice.  Extending LARC education to primary care 395 
can assist the large number of women who access general practice for their health care. In 396 
many countries internationally, there is a paucity of specialised contraceptive clinics, and 397 
general practice is the main provider of women’s sexual and reproductive health services, 398 
particularly contraception.  399 
Research Implications 400 
While the trial demonstrated that a complex intervention involving training FPs to deliver 401 
structured effectiveness-based contraceptive counselling and making available timely access 402 
to LARC insertion clinics is effective at increasing LARC uptake, we cannot identify which 403 




intervention and control groups the intervention group had higher uptake of the hormonal 405 
IUS. This may indicate the importance of timely access to insertion clinics especially since 406 
only 44% of intervention fidelity checks witnessed the delivery of structured efficacy based 407 
contraceptive counselling. 408 
Strengths and Limitations 409 
The strengths of this study include the evaluation of the intervention in routine general 410 
practices and examination of the sustainability of the effects after the availability of the 411 
intervention had ceased. We undertook randomization of doctors rather than women in our 412 
cluster randomized controlled trial. This reduced contamination which would have occurred 413 
if women had been individually randomized, as individual women in the same practice may 414 
have been in different arms of the study.  415 
The intervention effect and the high cohort retention rate are also strengths providing us with 416 
the opportunity to demonstrate the longevity of the eff ct of the ACCORd intervention. 417 
While the use of LARCs in our population of women participants was lower at baseline 418 
(13%) than a recently reported population based survey involving a younger population 419 
(19%),28 it was similar to another Australian study which reported 11% LARC use.10 At six 420 
months, 44% of our intervention group and 29% of our control group were using  LARCs, 421 
reflecting an increase in LARC use over both groups (but significantly higher in the 422 
intervention group), and a higher proportion of current LARC users than recently reported. At 423 
12 months the increase was sustained with 47% of women in the intervention group and 33% 424 
in the control group. Longer follow up would have allowed us to determine if this rise in 425 




Our trial had several limitations. Masking of doctors and women during implementation was 427 
not feasible and because women’s outcomes were self-reported there may have been some 428 
bias responding to the survey questions. 429 
Withdrawal of both FPs (58% in the intervention group and 52% in the control group) and 430 
women participants (29% across both groups) from the s udy was higher than the 10% 431 
anticipated. This may reflect the difficulty some FPs had completing a six-hour online 432 
learning module, an inability of participants to spend the required time to complete the study, 433 
and/or poor incentives for both FPs and women participants. Future research should focus on 434 
determining whether other approaches to training FPs which are less time consuming such as 435 
academic detailing or involvement in an online community of practice achieve the same 436 
outcomes.  437 
We originally designed the study with 24 FPs in each rm, and each FP recruiting 24 women. 438 
However, once recruitment began it was apparent that some FPs would not reach the target of 439 
24 women in the required time. For some FPs this was because their patient population did 440 
not include many women of reproductive age. This wap rticularly the case for male FPs and 441 
female FPs who were themselves over 45 years. To compensate we decided to recruit more 442 
FPs, and we also allowed FPs (who were able) to recruit more than 24 women.  443 
Setting one of the primary outcomes as LARC insertion at four weeks was problematic for 444 
some women as there was a delay in returning to the FP for a contraceptive consultation, and 445 
a further delay if LARC referral / insertion was instigated. A more clinically meaningful 446 
outcome may have been LARC use at 6 months or 12 months, to reflect LARC insertion and 447 
retention over time.   448 
Our sample of FPs as well as their women patients were highly educated. We anticipated that 449 




ACCORd FPs had undertaken additional training in cotraception. This rate was however 451 
well balanced across both intervention and control g ups, making the effect of our 452 
intervention even more compelling. Non-inclusion of women who spoke limited English  453 
may affect the generalizability of our findings to w men of non-English speaking 454 
backgrounds.  Additionally, our sample of women was from the metropolitan area, and rural 455 
women may face greater challenges with access to LARC insertion. The small number of 456 
male FPs in our study may impact on the generalizabi ty of the ACCORd intervention in 457 
general practice settings where there are larger proportions of male practitioners. 458 
The P-value for the outcome insertion at 4 weeks differed when calculated by the χ2 test, 459 
adjusted for clustering and stratification, and binary regression model with GEE. However, 460 
the χ2 test can be less powerful than binary regression and so may not detect a difference if it 461 
exists and the binary regression model will provide an unbiased estimate with appropriate 462 
confidence interval coverage. Hence, we consider the esults from the binary regression 463 
model to be more informative.29 30 464 
Conclusions 465 
In conclusion the provision of training to FPs in structured efficacy- focussed contraceptive 466 
counselling together with providing FPs with a rapid referral pathway to LARC insertion 467 
clinics results in increased LARC uptake. Implementation of this approach in family 468 
medicine practice settings more broadly, particularly in contexts where free contraception is 469 
not feasible, and specific sexual and reproductive health services are either not available or 470 
accessible could lead to reductions in unplanned prgnancies and abortion. 471 
 472 
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Number of family physicians 25 32 57 
Gender Male 2 (8.0) 4 (12.5) 6 
Female 23 (92.0) 28 (87.5) 51 
Age group 25 to 34 3 (12.0) 2 (6.3) 5 
35 to 54 17 (68.0) 24 (75.0) 41 
55 and over 5 (20.0) 6 (18.8) 11 
Inserts IUDs* No 22 (88.0) 27 (84.4) 47 
Yes 3 (12.0) 5 (15.6) 8 
Inserts implants No 7(28.0) 10 (31.3) 17 




1 to 4 3 (12.0) 3 (9.4) 6 
5 to 9 1 (4.0) 4 (12.5) 5 
10 or more 21 (84.0) 25 (78.1) 46 
Specific training in 
contraception 
No 19 (76.0) 24 (75.0) 43 
Yes 6 (24.0) 8 (25.0) 14 
Trained to insert 
IUDs* 
No 15 (60.0) 21 (65.6) 36 
Yes 10 (40.0) 11 (34.4) 21 
Women participants 




Age  16 to 24 years 104 (33.9) 163 (37.6) 267 
25 to 34 years 111 (36.2) 173 (40.0) 284 
35 to 45 years 92 (30.0) 97 (22.4) 189 
Parity 0 207 (67.4) 313 (72.3) 520 
 1 24 (7.8) 32 (7.4) 56 
2 53 (17.3) 71 (16.4) 124 
3 or more 23 (7.5) 17 (3.9) 40 
LARC† use at 
baseline# 
No 266 (87.2) 379 (87.5) 645 
Yes 39 (12.8) 54 (12.5) 93 
Marital status‡ Married/de facto 133 (43.5) 184 (42.5) 317 
Single 173(56.5) 249 (57.5) 422 
Household income‡ ≤$600 per week 75 (30.4) 126 (35.3) 201 
> $600 per week 172 (69.6) 231 (64.7) 403 
Education  Completed less than Year 12  99 (32.2) 144 (33.3) 243 




No 249 (81.1) 363 (83.8) 612 
Yes 58 (18.9) 70 (16.2) 128 
Previous abortion No 267 (87.0) 390 (90.1) 657 
Yes 40 (13.0) 43 (9.9) 83 
 593 
*IUD: Intrauterine device 594 
† LARC: Long-acting reversible contraceptives 595 




Table 2: Outcomes at 4 weeks, 6 months and 12 months* 597 
 598 
  Number of women with 
information available 
Number (%) with outcome     








Group          
n (%) 
Prevalence ratio 
 (95% CI) † 
P-value Difference  
(95% CI) † 
P-value‡ 
Outcomes 
at 4 weeks 
LARC §inse
rtions 





at any time 
in 6 months 











LARC § use 
at any time 
in 12 
months 




219 308 102 (46.6%) 101 (32.8%) 1.5 (1.2 to 2.0) 0.0015 16.7 (7.4 to 26.0) <0.001 
 599 
*Adjusted for clustering by the family physician and stratified by whether the family physician inserted long-acting reversible contraceptives 600 
† CI: Confidence intervals 601 
‡
The statistical test in the tables is the Wald Chi-square test from the fitted binary regression models with generalized estimating equation. 602 
§ 
LARC: Long-acting reversible contraceptives 603 












































16 (6.5) 13 (5.2) 3 (1.2) 114 (46.0) 4 (1.6) 61 (24.6) 14 (5.6) 34 (13.7) 9 (3.6)  
Control 
(n=378) 
16 (4.2) 29 (7.7) 5 (1.3) 173 (45.8) 1 (0.3) 87 (23.0) 9 (2.4) 65 (17.2) 7 (1.9)  
Contraception 
method  
recorded  within 






39(15.7) 2 (0.8) 28 (11.3) 3 (1.2) 94 (37.9) 3 (1.2) 30 (12.1) 2 (0.8) 33 (13.3) 5 (2.0) 9 (3.6) 
Control 
(n=378) 
28 (7.4) 4 (1.1) 45 (11.9) 4(1.1) 162 (42.3) 2 (0.5) 64 (16.9) 2 (0.5) 58 (15.3) 2 (0.5) 7 (1.9) 












65 (30.4) 5 (2.3) 25 (11.7) 3 (1.4) 54 (25.2) 1 (0.5) 74 (34.6) 31 (14.5) 4 (1.9) 5 (2.3)  
Control 
(n=311) 
36 (11.6) 8 (2.6) 47 (15.1) 3 (1.0) 122 (39.2) 3 (1.0) 101 
(32.5) 








63 (28.8) 6 (2.7) 26 (11.9) 4 (1.8) 68 (31.1) 0 (0) 67 (30.6) - 4 (1.8) 4 (1.8)  
Control 
(n=308) 
39 (12.7) 11 (3.6) 49 (15.9) 2 (0.7) 106 (34.4) 2 (0.7) 98 (31.8) - 15 (4.9) 3 (1.0)  
*IUS: Intrauterine system †IUD: Intrauterine device  
‡
OCP: oral contraceptive pill (combined or progestogen only) 605 
§
 Note 78% of women had the baseline survey completed aft r the initial FP visit. For these women baseline contraception information was derived from the data 606 
collected at this initial visit. Only one form of contraception was recorded at these visits however the baseline questionnaire allowed for multiple forms. To reconcile 607 
the two data sources women have been assigned the most effective method if they recorded use of multiple methods.  The baseline questionnaire also did not 608 
differentiate between hormonal and copper intrauterine devices. 609 
||Note only one form of contraception recorded at FP visits 610 




Table 4: Participant quality of life (QOL scales) at baseline, 6 and 12 months  
 
 Baseline 6 months 12 months 
Scale Mean (SD) Mean 
(SD) 
Difference 
(95% CI) * 
P-value Mean (SD) Difference 
(95% CI) * 
P-value 
Physical functioning 
Intervention group 93 (11.7) 94 (10.7) 2.4 (0.04 to 4.7) 0.05 93 (12) 1.3 (-1.4 to 4.1) 0.34 
Control group 93 (14.9) 91 (16.9)   91 (17.6)  
Role limitations due to physical health 
Intervention group 73 (38.9) 87 (27.7) 5.4 (-0.2 to 1.1) 0.06 87 (29.5) 2.2 (-2.7 to 7.2) 0.37 
Control group 76 (35.3) 83 (31.6)   84 (32.4)  
Role limitations due to emotional problems 
Intervention group 73 (36.6) 74 (37.8) 1.3 (-5.2 to 7.8) 0.70 75 (36) 0.6 (-4.7 to 5.9) 0.83 
Control group 75 (36.4) 73 (39.0)   74 (38.5)  
Energy/fatigue 
Intervention group 55 (19.3) 51 (19.9) 0.4 (-2.6 to 3.3) 0.81 51 (21.1) -0.5 (-4.1 to 3.2) 0.80 





Intervention group 76 (15.1) 71 (17.2) 2.3 (-0.2 to 4.8) 0.07 72 (16.7) 0.8 (-1.9 to 3.5) 0.56 
Control group 75 (16.6) 69 (19.1)   70 (18.3)  
Social functioning 
Intervention group 82 (18.7) 84 (18.1) 2.3 (-1.6 to 6.1) 0.24 82 (19.9) -0.1 (-3.0 to 2.8) 0.94 
Control group 82 (19.6) 82 (20.3)   82 (20.2)  
Pain 
Intervention group 74 (21.5) 81 (18.4) 2.2 (-0.6 to 5.0) 0.13 78 (21.9) -0.3 (-3.1 to 2.4) 0.81 
Control group 76 (21.7) 79 (20.7)   79 (21.0)  
General health 
Intervention group 71 (19.1) 68 (18.4) 2.2 (1.2, 3.2) <0.0001 67 (19.4) 0.7 (-2.9 to 3.3) 0.62 
Control group 70 (19.8) 66 (19.6)   66 (19.5)  
* adjusted for clustering by family physician, stratification (whether family physician  inserts long-acting reversible contraceptives and baseline 
values 
Note: Q23 of DF-36 which contributes to the Energy/Fatigue scale was not included in the survey.  
Results were similar when missing data are imputed assuming women with missing outcome data have similar outcomes as (1) those from same 






Table A1: Subgroup analyses. Insertion of long-acting reversible contraceptives at 4 weeks 
 
    Intervention Control   
Subgroup 
variable 



























16 to 24 87 20 (23.0) 67 (77.0) 142 17 (12.0) 125 (88.0) 0.61 
25 to 34 84 17 (20.2) 67 (79.8) 153 23 (15.0) 130 (85.0) 
35 to 45 77 11 (14.3) 66 (85.7) 83 5 (6.0) 78 (94.0) 
Parity 
  
No children 164 33 (20.1) 131 (79.9) 275 36 (13.1) 239 (86.9) 0.08 






2 children 44 7 (15.9) 37 (84.1) 63 5 (7.9) 58 (92.1) 






103 18 (17.5) 85 (82.5) 160 14 (8.8) 146 (91.3) 0.23 
Single 144 30 (20.8) 114 (79.2) 218 31 (14.2) 187 (85.8) 
Household 
income 
≤$600 per week 59 10 (16.9) 49 (83.1) 110 18 (16.4) 92 (83.6) 0.31 




Year 12 or 
below 
84 18 (21.4) 66 (78.6) 127 18 (14.2) 109 (85.8) 0.64 




No 200 38 (19.0) 162 (81.0) 319 33 (10.3) 286 (89.7) 0.18 
Yes 48 10 (20.8) 38 (79.2) 59 12 (20.3) 47 (79.7) 
Previous 
abortion 
No 214 40 (18.7) 174 (81.3) 340 36 (10.6) 304 (89.4) 0.22 









No 219 179 (81.7) 40 (18.3) 333 33 (9.9) 300 (90.1) 0.82 
Yes 29 8 (27.6) 21 (72.4) 45 12 (26.7) 33 (73.3) 
 




Table A2: P-values from Chi-Squared Mantel-Haenszel analysis (MHA) and Binary regression models with Generalized Estimating 
Equations (GEE) for Outcomes  
 
 GEE P-value  MHA P-value 
Outcomes at 4 weeks after initial 
consult 
Referred for LARC* insertion 0.0001 0.0002 
LARC insertions 0.033 0.20 
Outcomes at 6 months LARC use at any time in 6 months <0.0001 0.00053 
Currently using a LARC 0.0007 0.003 
Outcomes at 12 months LARC use at any time in 12 months 0.0002 0.0011 
Currently using a LARC 0.0015 0.0086 
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Family physicians (FPs) assessed for 
eligibility (n=271) 
Excluded (n=184) 
 Not meeting inclusion criteria (n=31) 
 Declined to participate (n=143) 
 Other reasons (n=10) 
307 consented women from 25 intervention FPs 






who recruited at least one 
woman 
 n=25 
Allocated to intervention (n=43) 
 




433 consented women from 32 control FPs 









Withdrawn and recruited 
no women (n=18):  
 12 of whom did not 
complete 




Withdrawn and recruited 




248 women with data available from Standardized Data 
Collection Forms from 24 FPs. 





378 women with data available from Standardized Data 
Collection Forms from 31 FPs.  




214 women with data available from 6 month questionnaire 
from 25 FPs. 





311 women with data available from 6 month 
questionnaire from 32 FPs.  





7 FPs withdrew after 
recruiting at least one 
woman and were included in 
the analysis 
11 FPs withdrew after 
recruiting at least one 
woman and were included 
in the analysis 
219 women with data available from 12 month questionnaire 
from 25 FPs. 
Cluster size: mean=9, range 1-27 
 
 
308 women with data available from 12 month 
questionnaire from 32 FPs.  
Cluster size: mean=10, range =1-22 
 
 
Women accessed iPad at FP’s practice n=2,258 
 Did not complete survey: n=328.  
 Ineligible: n=898  
 Completed survey but did not consent n=292 
Reasons for not consenting:                                                               
                                           Intervention   Control 
       Unable to be contacted:           62              109 
       No longer interested:               10                19 
      Too busy:                                 11                25 
      Ineligible:                                  5                  8 
      Other                                        15                28 
      Total                                       103              189 
Eligible women who consented: N=740 
 
 Eligible women who consented: N=740 
 
